ClinicalTrials.gg
CompletedNCT00599196Updated Oct 2, 2014Results posted

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

A Phase 3 interventional study of Rotigotine in Early Stage Parkinson's Disease, sponsored by UCB Pharma. Completed at 63 sites in 20 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
381
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
5th of 42
381 · median 123
Started
2002
with 2 others
Phase 3
20 of 44
none open now
Registered
16th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 5th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2002, is one of 20 in phase 3, and was the 16th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease

Read the detailed description

This is the open-label extension to the randomized, double-blind, placebo- and ropinirole-controlled SP513 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease

03

Conditions studied

  • Early Stage Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro®
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed six months of maintenance treatment in the SP513 double-blind trial

Exclusion criteria

Exclusion Criteria:

  • Subjects who had an ongoing serious adverse event from SP513 double-blind trial that was assessed as related to study medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine

    Drug: Rotigotine

Interventions

  • Rotigotine trans-dermal patches, once daily: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours); Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours. After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.

    Also known as: Neupro®

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Adverse Event During This Open-label Extension Study

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: six years

Secondary outcomes

  1. Number of Subjects Who Withdrew From the Trial Due to an Adverse Event

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: six years

  2. Mean Epworth Sleepiness Scale Score During the Open-label Extension

    The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

    Time frame: Visit 10 (end of year 1), Visit 14 (end of year 2), Visit 18 (end of year 3), Visit 22 (end of year 4), Visit 26 (end of year 5), Visit 30 (end of year 6), End of Treatment (last study visit or early withdrawal visit)

07

Results

Posted Jan 18, 2010

Participant flow

An Open-Label Extension to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects with Early-Stage Idiopathic Parkinson's Disease from August 2002 to December 2008

Participant flow — Overall Study
MilestoneRotigotine
Started381
Completed0
Not completed381
Withdrew: Lack of efficacy22
Withdrew: Adverse event93
Withdrew: Unsatisfactory compliance of subject3
Withdrew: Subject withdrew consent43
Withdrew: Study ended per sponsor197
Withdrew: Lost to follow-up17
Withdrew: Other: patient leaving for israel1
Withdrew: Other: spouse withdrew consent1
Withdrew: Other: diagnosis no longer idiopathic pd1
Withdrew: Other: pt moved to australia1
Withdrew: Other: patient stopped due to moving1
Withdrew: Other: inv switched dopamine agonist1

Outcome measures

PrimaryNumber of Subjects With at Least One Adverse Event During This Open-label Extension Study

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
six years
Reported as:
Number · Subjects
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
SubjectsRotigotine
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study369
SecondaryNumber of Subjects Who Withdrew From the Trial Due to an Adverse Event

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
six years
Reported as:
Number · Subjects
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event
SubjectsRotigotine
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event93
SecondaryMean Epworth Sleepiness Scale Score During the Open-label Extension

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

Time frame:
Visit 10 (end of year 1), Visit 14 (end of year 2), Visit 18 (end of year 3), Visit 22 (end of year 4), Visit 26 (end of year 5), Visit 30 (end of year 6), End of Treatment (last study visit or early withdrawal visit)
Reported as:
Mean · Score on a scale
Mean Epworth Sleepiness Scale Score During the Open-label Extension
Score on a scaleRotigotine
Visit 10 (end of year 1) (n=375)5.8 ± 3.8
Visit 14 (end of year 2) (n=375)6.2 ± 4.1
Visit 18 (end of year 3) (n=375)6.7 ± 4.5
Visit 22 (end of year 4) (n=375)6.7 ± 4.6
Visit 26 (end of year 5) (n=375)6.7 ± 4.5
Visit 30 (end of year 6) (n=375)6.8 ± 4.5
End of Treatment (n=377)6.8 ± 4.5

Adverse events

Collected over up to 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—131/380 (34.5%)323/380 (85%)
Most frequent serious events
Showing 10 of 171
Most frequent serious events
EventRotigotine
OsteoarthritisMusculoskeletal and connective tissue disorders11/380
Myocardial infarctionCardiac disorders10/380
FallInjury, poisoning and procedural complications9/380
Parkinson's diseaseNervous system disorders9/380
Femoral neck fractureInjury, poisoning and procedural complications6/380
CholelithiasisHepatobiliary disorders5/380
Femur fractureInjury, poisoning and procedural complications5/380
PneumoniaInfections and infestations4/380
HallucinationPsychiatric disorders4/380
Inguinal herniaGastrointestinal disorders3/380
Most frequent other events
Showing 10 of 27
Most frequent other events
EventRotigotine
SomnolenceNervous system disorders146/380
NauseaGastrointestinal disorders72/380
Oedema peripheralGeneral disorders71/380
Back painMusculoskeletal and connective tissue disorders57/380
DizzinessNervous system disorders51/380
InsomniaPsychiatric disorders48/380
Application site reactionGeneral disorders45/380
FallInjury, poisoning and procedural complications43/380
HypertensionVascular disorders41/380
DepressionPsychiatric disorders38/380

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years215
>=65 years165
Age, Continuous
Age, Continuous(years)Rotigotine
Mean61.6 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female150
Male230
Region of Enrollment
Region of Enrollment(participants)Rotigotine
Finland16
Spain10
Austria12
Israel30
United Kingdom38
Italy9
Switzerland4
France10
Czech Republic44
Hungary17
Poland65
Belgium12
Croatia17
Australia7
South Africa42
Germany7
Norway4
Netherlands5
New Zealand19
Sweden12
08

Study locations

63 sites
  • Concord, Australia
  • Darlinghurst, Australia
  • East Gosford, Australia
  • Westmead, Australia
  • Innsbruck, Austria
  • Wien, Austria
  • Brussels, Belgium
  • Hoboken, Belgium
  • Zagreb, Croatia
  • Brno, Czech Republic
  • Ostrava, Czech Republic
  • Plzen, Czech Republic
  • Espoo, Finland
  • Kuopio, Finland
  • Lappeenranta, Finland
  • Oulu, Finland
  • Pori, Finland
  • Aix-en -Provence, France
  • Caen Cedex, France
  • Toulouse Cedex, France
  • Aachen, Germany
  • Dresden, Germany
  • Kiel, Germany
  • Marburg, Germany
  • Budapest, Hungary
  • Miskolc, Hungary
  • Pecs, Hungary
  • Hadera, Israel
  • Petach-Tikva, Israel
  • Tel Aviv, Israel
  • Milano, Italy
  • Padova, Italy
  • Pozzilli, Italy
  • Breda, Netherlands
  • Geldrop, Netherlands
  • Auckland, New Zealand
  • Christchurch, New Zealand
  • North Shore, New Zealand
  • Wellington, New Zealand
  • Stavanger, Norway
  • Trondheim, Norway
  • Gdansk, Poland
  • Katowice, Poland
  • Krakόw, Poland
  • Lublin, Poland
  • Mosina k/Poznania, Poland
  • Olsztyn, Poland
  • Warszawa, Poland
  • Cape Town, South Africa
  • Pretoria, South Africa
  • Barcelona, Spain
  • Pamplona, Spain
  • Karlstad, Sweden
  • Stockholm, Sweden
  • Bern, Switzerland
  • Lausanne, Switzerland
  • Birmingham, United Kingdom
  • Blackpool, United Kingdom
  • Glasgow, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
  • Newcastle Upon Tyne, United Kingdom
  • Swansea, United Kingdom
09

References and documents

Publications

  • Giladi N, Boroojerdi B, Surmann E. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. J Neural Transm (Vienna). 2013 Sep;120(9):1321-9. doi: 10.1007/s00702-013-1001-5. Epub 2013 Mar 19. PubMed 23508526 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2007
First posted
Jan 23, 2008
Start
Aug 2002
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 18, 2010
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00599196
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 23, 2008
Start date
Aug 2002
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 18, 2010
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion